METUPUK are delighted by the Scottish Medicines Consortium (SMC) approval of two new drugs for metastatic breast cancer for use by NHS Scotland

The Scottish Medicines Consortium (SMC) has approved today:

Trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic breast cancer in adults who have received two or more prior anti-HER2 based therapies for routine use on the NHS in Scotland.

Tucatinib (Tukysa) with trastuzumab and capecitabine for treating HER2-positive unresectable locally advanced or metastatic breast cancer after two or more anti-HER2 therapies for routine use on the NHS in Scotland.

Statistics for Metastatic Breast Cancer

Statistics for Metastatic Breast Cancer

We started our campaign in Metastatic May with some information about treatment lines and it really caused a bit of a stir, especially on Instagram.

Why? Because people don’t want to think that this disease is going to kill us. We have to remain positive. We have to see the chink of light and I agree we all have to have hope. That was my introduction. We need hope.